|
Secondary metabolite¿¡ ´ëÇÑ ³»¿ë ÀÔ´Ï´Ù.( ±×·¡ÇÁ ÷ºÎ) ¹°ÁúºÐ¼® / PURPOSE ÀÌÂ÷ ´ë»ç»ê¹°À» ¾Ë°í HPLC¸¦ ÅëÇØ ¹°ÁúÀÇ À¯¹«¸¦ È®ÀÎÇÑ´Ù. Introduction 1. Lovastatin Monacolin K inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, and are effective in lowering plasma cholesterol levels in human as¡¦ |
|
|
|
|
|
# The context for change - ±³À°ÀÇ ¼ö´ÜÀ¸·Î¼ Áö¸®ÀÇ °¡´É¼ºÀÇ ¹ß´Þ¿¡ ÀÖ¾î, 1950³â´ë ¸»¢¦60³â´ë, ±³À°¿¡¼ÀÇ ±Ùº»ÀûÀÎ... / # The context for change - ±³À°ÀÇ ¼ö´ÜÀ¸·Î¼ Áö¸®ÀÇ °¡´É¼ºÀÇ ¹ß´Þ¿¡ ÀÖ¾î, 1950³â´ë ¸»¢¦60³â´ë, ±³À°¿¡¼ÀÇ ±Ùº»ÀûÀÎ º¯È, ±³°úÀÇ º»Áú¿¡ °üÇÑ °üÁ¡ÀÇ º¯È¿¡ µû¸¥ ±³À°°úÁ¤ÀÇ º»Áú¿¡ ´ëÇÑ »ç°íÀÇ ¹ß´ÞÀÌ Áß¿äÇÏ´Ù. (Á¤ÀÇÀû ¿µ¿ª, °³³ä ÇнÀ, ¿ø¸®ÀÇ ÀÌ¡¦ |
|
|
|
|
|
6. SOAP note ÀÌÂ÷¼º ÆÄŲ½¼Áõ(secondary parkinsonism) ȯÀںР/ 1. Subjective information 2. Objective information 3. Assessment 4. Plan / 1. Subjective information ȯÀÚ´Â ÃÖ±Ù ¸î °³¿ù°£ Áõ»óÀÌ ¾ÇÈµÈ °ÍÀ¸·Î ´À³¢°í ÀÖ´Ù. óÀ½¿¡´Â °¡º¿î ¼Õ ¶³¸²ÀÌ ÀÖ¾ú°í, ƯÈ÷ ¿À¸¥ÂÊ ¼Õ¿¡¼ ´õ µÎµå·¯Á³´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼Õ ¶³¸²ÀÌ ½ÉÇØÁö°í, Á¡Â÷ ¿ÞÂÊ ¼Õ°ú ´Ù¸®·Îµµ ÆÛÁ³¡¦ |
|
|
|
|
|
6. SOAP note ÀÌÂ÷¼º ÆÄŲ½¼Áõ(secondary parkinsonism) ȯÀںР/ 1. Subjective information 2. Objective information 3. Assessment 4. Plan / 1. Subjective information ȯÀÚºÐÀº 60¼¼ ³²¼ºÀ¸·Î, ÃÖ±Ù ¸î °³¿ù°£ ÁÂÃø ¼ÕÀÇ ¶³¸²°ú °æÁ÷À» °æÇèÇÏ°í ÀÖ´Ù°í ÇÑ´Ù. óÀ½¿¡´Â ÀϽÃÀûÀÎ Áõ»óÀ¸·Î »ý°¢ÇßÁö¸¸ Á¡Â÷ Áõ»óÀÌ ½ÉÇØÁ³°í, ÀÏ»ó»ýÈ°¿¡ ¿µÇâÀ» ¹ÌÄ¡±â ½ÃÀÛÇß´Ù°í ÇÑ´Ù. ƯÈ÷¡¦ |
|
|
|
|
|
Secondary malignant neoplasm of liver and intrahepatic bile duct ÄÉÀ̽º ¸®Æ÷Æ® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê 2. ¹®Çå°íÂû 3. Áø´Ü°Ë»ç 4. ¾à¹° 5. °£È£°úÁ¤ 6. °á·Ð 7. Reference 8. ½Ç½À¼Ò°¨¹® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê PBLÀ» ÅëÇÑ °£È£»ç·Ê¿¡¼´Â °£ÀÇ ÀÌÂ÷ ¾Ç¼º ½Å»ý¹°°ú ´ã°ü ³» ¾Ç¼º ½Å»ý¹°ÀÇ »ç·Ê¸¦ ´Ù·ç°Ô µÈ´Ù. ÀÌ´Â ÁÖ·Î ´Ù¸¥ Àå±â¿¡¼ ¹ß»ýÇÑ ¾ÏÀÌ ÀüÀÌµÇ¾î °£°ú¡¦ |
|
|
|
|
|
¾Ïº´µ¿ case study (bone tumor, secondary malignant neoplasm of bone) / 1. ¼·Ð (1) »ç·Ê¿¬±¸ÀÇ Çʿ伺 (2) ¹®Çå°íÂû 2. º»·Ð (1) °Ç°»çÁ¤ (2) Áø´Ü ¹× Ä¡·á (3) Ä¡·á°æ°ú ¹× °èȹ (4) °£È£Áø´Ü 3. °á·Ð / 1. ¼·Ð ¾Ïº´µ¿¿¡¼ÀÇ ÄÉÀ̽º ½ºÅ͵ð´Â º¹ÀâÇÏ°í ´Ù¾çÇÑ È¯ÀÚ Äɾ Æ÷ÇÔÇϸç, ƯÈ÷ »À Á¾¾çÀ̳ª ÀüÀ̼º »À Á¾¾çÀÇ °æ¿ì ±× º¹À⼺ÀÌ ´õ¿í µÎµå·¯Áø´Ù. »À Á¾¾ç¡¦ |
|
|
|
|
|
Secondary malignant neoplasm of liver and intrahepatic bile duct ÄÉÀ̽º ¸®Æ÷Æ® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê 2. ¹®Çå°íÂû 3. Áø´Ü°Ë»ç 4. ¾à¹° 5. °£È£°úÁ¤ 6. °á·Ð 7. Reference 8. ½Ç½À¼Ò°¨¹® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê °£È£»ç´Â ȯÀÚÀÇ Àü¹ÝÀûÀÎ °Ç° »óŸ¦ Æò°¡ÇÏ°í, Ä¡·á °úÁ¤¿¡¼ Á÷¸éÇÏ´Â ´Ù¾çÇÑ ¹®Á¦¸¦ ÀÌÇØÇÏ°í °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇØ¾ß ÇÑ´Ù. ƯÈ÷ °£¡¦ |
|
|
|
|
|
¾Ïº´µ¿ case study (bone tumor, secondary malignant neoplasm of bone) / 1. ¼·Ð (1) »ç·Ê¿¬±¸ÀÇ Çʿ伺 (2) ¹®Çå°íÂû 2. º»·Ð (1) °Ç°»çÁ¤ (2) Áø´Ü ¹× Ä¡·á (3) Ä¡·á°æ°ú ¹× °èȹ (4) °£È£Áø´Ü 3. °á·Ð / 1. ¼·Ð ¾Ïº´µ¿¿¡¼ÀÇ »ç·Ê ¿¬±¸´Â ȯÀÚÀÇ »ýÁ¸°ú Àü¹ÝÀûÀÎ »îÀÇ Áú Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â Áß¿äÇÑ È°µ¿ÀÌ´Ù. ƯÈ÷ »À Á¾¾ç ¹× ÀÌÂ÷ ¾Ç¼ºÁ¾¾ç°ú °°Àº º¹ÀâÇÑ »ç·Ê´Â¡¦ |
|
|
|
|
|
1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯´Â ´Ù¾çÇÑ ½ÇÇè¿¡¼ ºñƯÀÌÀûÀÎ °áÇÕÀ» ¿¹¹æÇÏ°í.. / 1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ 2. blockingÀ» ¼öÇàÇϱâ À§ÇØ »ç¿ëÇÏ´Â ½Ã¾à 3. Western blot Ç×ü ¹ÝÀÀ ½Ã primary antibody¿Í secondary antibody·Î ±¸ºÐÇÏ¿© »ç¿ëÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡ 4. Âü°í¹®Çå / 1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ Membran¡¦ |
|
|
|
|